Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedJul 27, 2026
DataAggregated Company Financials
Companies47
  • 7D-0.9%
  • 3M5.0%
  • 1Y21.3%
  • YTD15.6%

Last week, the Biotech industry hasn't moved much but BioArctic is up 3.1% in that time. The past year has been better, since the industry has gained 21% in that time. Looking forward, earnings are forecast to grow by 32% annually.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 27 Jul 2026SEK 244.3bSEK 40.1b-SEK 5,681,898,890.0633.7x-43x6.1x
Wed, 24 Jun 2026SEK 248.6bSEK 38.4b-SEK 6,193,071,421.6135.7x-40.1x6.5x
Fri, 22 May 2026SEK 249.5bSEK 38.4b-SEK 6,036,212,552.7425.1x-41.3x6.5x
Sun, 19 Apr 2026SEK 241.4bSEK 38.5b-SEK 5,607,485,620.7817.7x-43x6.3x
Tue, 17 Mar 2026SEK 216.1bSEK 38.5b-SEK 5,720,272,654.2617.1x-37.8x5.6x
Thu, 12 Feb 2026SEK 227.5bSEK 38.6b-SEK 5,525,674,772.3828.2x-41.2x5.9x
Sat, 10 Jan 2026SEK 215.2bSEK 38.1b-SEK 556,297,658.1836x-386.9x5.7x
Mon, 08 Dec 2025SEK 209.4bSEK 38.1b-SEK 603,799,286.9831.5x-346.9x5.5x
Wed, 05 Nov 2025SEK 205.7bSEK 37.3b-SEK 1,210,403,737.1138.2x-170x5.5x
Fri, 03 Oct 2025SEK 208.1bSEK 36.4bSEK 3.0b31.4x68.8x5.7x
Sun, 31 Aug 2025SEK 200.9bSEK 36.4bSEK 3.0b31.1x66.6x5.5x
Tue, 29 Jul 2025SEK 192.7bSEK 35.9bSEK 2.8b28.6x69.1x5.4x
Thu, 26 Jun 2025SEK 179.6bSEK 35.2bSEK 2.2b28x80.7x5.1x
Sat, 24 May 2025SEK 185.8bSEK 35.2bSEK 2.2b29.4x83.1x5.3x
Mon, 21 Apr 2025SEK 175.2bSEK 33.7bSEK 758.0m29x231.2x5.2x
Wed, 19 Mar 2025SEK 193.0bSEK 33.7bSEK 579.5m33.7x333.1x5.7x
Fri, 14 Feb 2025SEK 217.8bSEK 33.8bSEK 347.9m54.2x626.1x6.5x
Sun, 12 Jan 2025SEK 215.7bSEK 33.0b-SEK 4,418,472,612.01154.7x-48.8x6.5x
Tue, 10 Dec 2024SEK 212.8bSEK 33.0b-SEK 4,445,654,523.81143.3x-47.9x6.4x
Thu, 07 Nov 2024SEK 215.0bSEK 33.2b-SEK 4,478,456,953.44140.1x-48x6.5x
Sat, 05 Oct 2024SEK 207.5bSEK 31.4b-SEK 5,524,008,836.2648.6x-37.6x6.6x
Mon, 02 Sep 2024SEK 216.4bSEK 31.5b-SEK 5,518,037,354.7351.1x-39.2x6.9x
Wed, 31 Jul 2024SEK 197.8bSEK 31.4b-SEK 5,421,530,700.5443.7x-36.5x6.3x
Fri, 28 Jun 2024SEK 196.2bSEK 30.6b-SEK 5,398,410,255.8439.4x-36.3x6.4x
Sun, 26 May 2024SEK 193.4bSEK 30.6b-SEK 5,406,535,340.1039.4x-35.8x6.3x
Tue, 23 Apr 2024SEK 178.5bSEK 29.8b-SEK 5,265,765,392.2366.1x-33.9x6x
Thu, 21 Mar 2024SEK 184.7bSEK 29.8b-SEK 5,637,388,054.1657.7x-32.8x6.2x
Sat, 17 Feb 2024SEK 177.3bSEK 29.7b-SEK 5,668,408,815.3654x-31.3x6x
Mon, 15 Jan 2024SEK 190.3bSEK 28.7b-SEK 1,198,820,921.0060.5x-158.8x6.6x
Wed, 13 Dec 2023SEK 168.5bSEK 28.7b-SEK 1,200,358,818.0055.7x-140.4x5.9x
Fri, 10 Nov 2023SEK 162.4bSEK 28.7b-SEK 1,294,007,859.0051.2x-125.5x5.7x
Sun, 08 Oct 2023SEK 160.1bSEK 27.4b-SEK 2,017,078,379.0048.4x-79.4x5.9x
Tue, 05 Sep 2023SEK 153.8bSEK 27.4b-SEK 1,981,479,722.0053.4x-77.6x5.6x
Thu, 03 Aug 2023SEK 156.2bSEK 27.5b-SEK 1,534,855,086.0054.2x-101.7x5.7x
Price to Earnings Ratio

-101.7x


Total Market Cap: SEK 156.2bTotal Earnings: -SEK 1,534,855,086.00Total Revenue: SEK 27.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -39.7x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 13% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market0.87%
Healthcare-2.08%
Biotech-0.86%
Biotech-0.86%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BIOA B BioArcticSEK 309.403.1%
+SEK 816.2m		41.5%PE128.7x
HNSA Hansa BiopharmaSEK 39.4221.9%
+SEK 720.5m		42.0%PS21.2x
BONEX Bonesupport HoldingSEK 203.802.0%
+SEK 256.9m		-36.9%PE62.7x
EGTX Egetis TherapeuticsSEK 6.728.4%
+SEK 241.8m		10.3%PS49.5x
CRNO B Cereno ScientificSEK 4.959.5%
+SEK 133.6m		-48.8%PS23.1x

Latest News

HNSA
SEK 39.42
Hansa Biopharma
7D
21.9%
1Y
42.0%
Analysis Article • Jul 25

Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

The analysts might have been a bit too bullish on Hansa Biopharma AB (publ) ( STO:HNSA ), given that the company fell...
EGTX
SEK 6.72
Egetis Therapeutics
7D
8.4%
1Y
10.3%
Narrative Update • Jul 24

EGTX: Overweight Rating And New Price Objective Will Drive Reassessment

Analysts have lifted their fair value estimate for Egetis Therapeutics to SEK 11.00, citing the new SEK 23.00 price target alongside updated assumptions on discount rate, revenue growth, profit margin and future P/E multiples. What's in the News Analysts highlight a revised fair value estimate for Egetis Therapeutics at SEK 11.00, aligned with a SEK 23.00 price target based on updated assumptions for the discount rate, revenue outlook, profit margin and future P/E multiples.
ATORX
SEK 0.048
Alligator Bioscience
7D
-74.4%
1Y
-99.2%
SOBI
SEK 457.40
Swedish Orphan Biovitrum
7D
-1.0%
1Y
62.8%
BIOG B
SEK 115.60
BioGaia
7D
-7.4%
1Y
15.9%
Narrative Update • Jul 21

BIOG B: Dividend Power And Skincare Expansion Will Support Future Rerating

Analysts have trimmed their price target on BioGaia to SEK 152.50 from SEK 165.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. What's in the News BioGaia New Sciences AB expanded the BioGaia Skincare portfolio with two new products, Gentle Balm to Milk Wash and Soothing Face & Body Lotion, and introduced an updated design across the full range, targeting babies and children with dry, sensitive and atopic prone skin.
MVIR
SEK 1.72
Medivir
7D
3.6%
1Y
-16.2%
BONEX
SEK 203.80
Bonesupport Holding
7D
2.0%
1Y
-36.9%
Narrative Update • Jul 20

BONEX: Share Buybacks Will Support Bullish Case Despite Lowered Growth Assumptions

Analysts have reduced their price target for Bonesupport Holding to SEK275 from SEK310, reflecting updated assumptions around a slightly higher discount rate, more moderate revenue growth, a marginally stronger profit margin, and a lower future P/E multiple. What's in the News for Bonesupport Holding Bonesupport Holding AB (publ) plans to commence a share repurchase program on June 9, 2026, following a mandate from the Annual General Meeting on May 12, 2026.
VITR
SEK 85.20
Vitrolife
7D
-7.7%
1Y
-42.5%
CRNO B
SEK 4.95
Cereno Scientific
7D
9.5%
1Y
-48.8%
BIOA B
SEK 309.40
BioArctic
7D
3.1%
1Y
41.5%
SYNACT
SEK 18.48
SynAct Pharma
7D
-6.1%
1Y
-14.0%
VICO
SEK 11.22
Vicore Pharma Holding
7D
-1.2%
1Y
27.1%
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%
CURAS
DKK 18.40
Curasight
7D
-2.1%
1Y
517.4%
SANION
SEK 12.81
Saniona
7D
-1.8%
1Y
42.7%
IVACC
SEK 1.27
Intervacc
7D
8.9%
1Y
10.8%